{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009221","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.421301+00:00","generated_at":"2026-06-17T21:30:00.885928+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cyclerion reports $44.1M net loss in 2022; cash $13.4M; evaluating options for zagociguat","bullets":["Cash, equivalents & restricted cash $13.4M at Dec 31, 2022, down from $20.4M at Sep 30, 2022.","Net loss $44.1M for FY 2022 vs $51.6M in FY 2021; R&D spend $31.5M, G&A $14.5M.","Met with FDA in Q4 2022; filed for Orphan Drug Designation for zagociguat in MELAS.","Refined Phase 2b design for zagociguat; manufactured drug product to support the study.","Company actively evaluating capital, capabilities, or transactions to advance pipeline and maximize value."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009221","json":"https://secwatch.observer/filing/0000950170-23-009221.json","markdown":"https://secwatch.observer/filing/0000950170-23-009221.md","text":"https://secwatch.observer/filing/0000950170-23-009221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017023009221/0000950170-23-009221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017023009221/cycn-20230322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:30:00.885928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e359c787ebd00993bd2fa9b69d6b4182768524b","claim":"Cyclerion Therapeutics, Inc. reported the full year 2022 results: net income approximately $44.1 million.","evidence_excerpt":"Net loss was approximately $44.1 million for the full year 2022, as compared to $51.6 million for the full year 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1755237/000095017023009221/0000950170-23-009221-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2022"},{"label":"Net income","value":"approximately $44.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}